Doctors have long been mystified as to why HIV-1 rapidly sickens some individuals, while in others the virus has difficulties gaining a foothold. Now, a study of genetic variation in HIV-1 and in the cells it infects reported ...
Nov 20, 2014
0
0
If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow-up strategies. ...
Nov 3, 2014
0
0
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), ...
Sep 23, 2014
0
0
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia ...
Sep 16, 2014
0
0
Specific immune cells, known as T lymphocytes, have to be activated so that the body can develop long-term protection against infections. Previously, it was believed that this process only took place in the lymph nodes and ...
Sep 5, 2014
0
0
Researchers from UCL (University College London) have demonstrated how an interplay between nutrition, metabolism and immunity is involved in the process of aging.
Aug 24, 2014
6
0
(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...
Jul 24, 2014
0
0
(Medical Xpress)—Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukaemia.
Jul 9, 2014
0
0
US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear.
Jul 7, 2014
1
0
An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published ...
Jun 2, 2014
0
0
